Terminated PHASE3 INTERVENTIONAL 1-arm NCT00441558

A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).

Worldwide One-year Open-label Safety Study of Flibanserin in Women With HSDD

Sponsor: Sprout Pharmaceuticals, Inc

Conditions Sexual Dysfunctions, Psychological

Interventions Flibanserin

Updated 9 times since 2017 Last updated: May 14, 2014 Started: Feb 28, 2007 Primary completion: Aug 31, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

terminated for administrative reasons

Other terminated trials from Sprout Pharmaceuticals, Inc

More terminations from Sprout Pharmaceuticals, Inc

Other Sexual Dysfunctions, Psychological trials with similar outcome

Browse all Sexual Dysfunctions, Psychological trials

This PHASE3 trial investigates Sexual Dysfunctions, Psychological and is currently terminated or withdrawn. Sprout Pharmaceuticals, Inc leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE3

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sprout Pharmaceuticals, Inc

Data source: Sprout Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albequerque, United States , Anderson, United States , Ann Arbor, United States , Atlanta, United States , Aurora, United States , Austin, United States , Aventura, United States , Baltimore, United States , Barrie, Canada , Baton Rouge, United States and 142 more locations